پديد آورندگان :
Dal Ben D. نويسنده , Lambertucci C. نويسنده , Vittori S. نويسنده , Volpini R. نويسنده , Cristalli G. نويسنده
چكيده لاتين :
G-protein-coupled receptors (GPCRs) represent the largest known family of signal-transducing proteins and transmit signals
for light and many extracellular regulatory molecules. GPCRs are dysfunctional or dysregulated in several human diseases and are
estimated to be the targets of ~40% of the drugs used in clinical medicine today. Receptors for adenosine belong to this family,
and so far four subtypes, the A1, A2A, A2B, and A3, have been recognized. The activation of adenosine receptors (ARs) is largely
responsible for the variety of effects produced by adenosine throughout several organ systems. Based on the wide (and often
beneficial) effects attributed to the accumulation of endogenously released adenosine, it has long been considered that regulation
of ARs has considerable therapeutic potential. In this review, we focus on recent work on adenosine receptors as therapeutic
targets and, in particular, on molecular modelling support to adenosine receptors targeting.
